1
ALL1
Wellspring OphthalmicsYear
1
ALL1
2022DEALS // DEV.
1
ALL1
DevelopmentsCountry
1
ALL1
U.S.A1
ALL1
Not ApplicableTherapeutic Area
1
ALL1
OphthalmologyStudy Phase
1
ALL1
PreclinicalDeal Type
0
ALLProduct Type
1
ALL1
PeptideDosage Form
1
ALL1
Suspension/DropsLead Product
1
ALL1
CyclosporineTarget
1
ALL1
CalcineurinLead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Wellspring Ophthalmics Announces Receiving Its Second Patent for Novel Cyclosporine Dry Eye Therapy
Details : The Company’s intellectual property portfolio, which includes additional pending patents, covers a broad formulation platform of a unique suspension comprising aqueous, amorphous nanodispersions of cyclosporine.
Brand Name : Cyclosporine-Generic
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 20, 2022
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?